Efficacy of immune checkpoint inhibitors in different types of melanoma.
Immunotherapy
conjunctival melanoma
melanoma
uveal melanoma
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
02 01 2021
02 01 2021
Historique:
pubmed:
15
7
2020
medline:
22
6
2021
entrez:
15
7
2020
Statut:
ppublish
Résumé
Immunotherapy can be used for cutaneous, mucosal, uveal and conjunctival melanoma. Nevertheless, we cannot expect the same benefit from checkpoint inhibitors for all the types of melanoma. The different biological features can explain the variable efficacy. The main results obtained with immune checkpoint inhibitors in the various types of melanoma were reviewed.
Identifiants
pubmed: 32663057
doi: 10.1080/21645515.2020.1771986
pmc: PMC7872095
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4-13Références
Oncoimmunology. 2017 Jan 19;6(3):e1283462
pubmed: 28405510
J Clin Oncol. 2018 Feb 1;36(4):383-390
pubmed: 28671856
Cancer. 2016 Nov 15;122(21):3354-3362
pubmed: 27533633
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Pigment Cell Melanoma Res. 2014 Sep;27(5):835-8
pubmed: 24913711
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Lancet Oncol. 2016 Jul;17(7):976-983
pubmed: 27267608
Nat Med. 2019 Jun;25(6):941-946
pubmed: 31171878
Cancer. 2005 Mar 1;103(5):1000-7
pubmed: 15651058
Clin Cancer Res. 2008 Nov 1;14(21):6821-8
pubmed: 18980976
JAMA Oncol. 2019 Feb 1;5(2):187-194
pubmed: 30422243
Ann Oncol. 2015 Apr;26(4):798-803
pubmed: 25538176
Cancer. 2016 Nov 15;122(21):3344-3353
pubmed: 27533448
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Curr Oncol Rep. 2012 Oct;14(5):441-8
pubmed: 22661391
J Immunother Cancer. 2019 Jan 16;7(1):12
pubmed: 30651126
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Oncoimmunology. 2016 Feb 18;5(5):e1143997
pubmed: 27467964
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Am J Ophthalmol. 2008 Mar;145(3):418-423
pubmed: 18191091
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
J Immunother Cancer. 2019 Mar 25;7(1):83
pubmed: 30909967
Case Rep Oncol Med. 2017;2017:4623964
pubmed: 29214089
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Ocul Oncol Pathol. 2018 Jun;4(4):261-266
pubmed: 30643772
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Nat Commun. 2019 Jul 18;10(1):3163
pubmed: 31320640
Nat Med. 2019 Jun;25(6):936-940
pubmed: 31171879
Eur J Cancer. 2018 Dec;105:114-126
pubmed: 30447539
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
pubmed: 20160101
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Lancet Oncol. 2016 Nov;17(11):1558-1568
pubmed: 27622997
Ophthalmic Plast Reconstr Surg. 2017 Jul/Aug;33(4):e82-e85
pubmed: 27662198
J Clin Oncol. 2017 Jan 10;35(2):226-235
pubmed: 28056206
Lancet Oncol. 2012 May;13(5):459-65
pubmed: 22456429
Lancet Oncol. 2017 Mar;18(3):393-403
pubmed: 28162999
Eur J Cancer. 2018 Sep;101:236-243
pubmed: 30096704
Br J Cancer. 2018 Sep;119(6):670-674
pubmed: 30202085
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
Oncoimmunology. 2015 Mar 2;4(4):e1008814
pubmed: 26137403
Cancer Res. 2010 Jul 1;70(13):5213-9
pubmed: 20551059
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Lancet Oncol. 2017 May;18(5):611-622
pubmed: 28359784
Ophthalmol Clin North Am. 2005 Mar;18(1):143-50, ix
pubmed: 15763199
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
J Clin Oncol. 2015 Apr 1;33(10):1191-6
pubmed: 25713437
JAMA Ophthalmol. 2018 Nov 1;136(11):1236-1241
pubmed: 30352118
JAMA. 2016 Apr 19;315(15):1600-9
pubmed: 27092830
Eur J Cancer. 2017 Nov;86:115-124
pubmed: 28987768
Cancers (Basel). 2019 Jul 26;11(8):
pubmed: 31357439
JAMA Ophthalmol. 2017 Aug 1;135(8):891-892
pubmed: 28715523
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Front Oncol. 2019 Apr 05;9:232
pubmed: 31024839
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
PLoS One. 2017 Jun 8;12(6):e0178189
pubmed: 28594900
Ther Adv Med Oncol. 2019 Feb 19;11:1758835919830826
pubmed: 30815041
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Cancer. 1998 Oct 15;83(8):1664-78
pubmed: 9781962
Ann Oncol. 2013 Oct;24(10):2694-2698
pubmed: 23942774
Int J Mol Sci. 2019 Oct 31;20(21):
pubmed: 31683701
Cancer Biother Radiopharm. 2010 Dec;25(6):601-13
pubmed: 21204754
N Engl J Med. 2005 Nov 17;353(20):2135-47
pubmed: 16291983
Melanoma Res. 2017 Dec;27(6):591-595
pubmed: 29076951
Oncologist. 2015 Jun;20(6):648-52
pubmed: 25964307
Cancer. 2014 Jun 1;120(11):1695-701
pubmed: 24577748
Eur J Cancer. 2019 Sep;119:168-178
pubmed: 31445199
Cancer Immunol Immunother. 2019 Jul;68(7):1179-1185
pubmed: 31175402
Oral Oncol. 2000 Mar;36(2):152-69
pubmed: 10745167
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Ophthalmology. 2003 May;110(5):956-61
pubmed: 12750097
J Immunother Cancer. 2019 Nov 13;7(1):299
pubmed: 31722735
Lancet Oncol. 2018 May;19(5):672-681
pubmed: 29602646
Immunity. 1999 Oct;11(4):483-93
pubmed: 10549630
Oncotarget. 2017 May 20;8(33):54722-54734
pubmed: 28903377
JAMA Ophthalmol. 2017 Dec 1;135(12):1434-1437
pubmed: 29121185
Nat Med. 2019 Jun;25(6):929-935
pubmed: 31171876
Cancer Sci. 2019 Nov;110(11):3434-3441
pubmed: 31509303
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131